The U.S. Food and Drug Administration will hold an advisory panel meeting in November to examine the fast-emerging class of AI-enabled digital mental health devices. The agency's Digital Health Advisory Committee will meet on November 6 and focus on how these digital tools could help address a widening gap in access to mental health services in the United States, while also probing the unique risks they pose. There has been a sharp growth in AI-enabled digital mental health tools from chatbots